menu
    • menu
    [{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ginisortamab","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"InhaTarget Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InhaTarget Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InhaTarget Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InhaTarget Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Precirix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precirix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Undisclosed"},{"orgOrder":0,"company":"Precirix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precirix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Undisclosed"},{"orgOrder":0,"company":"Precirix","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2022","type":"Series B Financing","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Precirix \/ INKEF Capital","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ INKEF Capital"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CYAD-01","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GLPG5201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GLPG5301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NKR-2 CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celyad Oncology \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Celyad Oncology \/ IQVIA"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NKR-2 CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NKR-2 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Etherna","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etherna","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Etherna \/ European Commission","highestDevelopmentStatusID":"7","companyTruncated":"Etherna \/ European Commission"},{"orgOrder":0,"company":"Etherna","sponsor":"Vub","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etherna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Etherna \/ Vub","highestDevelopmentStatusID":"7","companyTruncated":"Etherna \/ Vub"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            InhaTarget Therapeutics

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            InhaTarget Therapeutics

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung ...

                            Details : Cisplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLPG5101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galapagos Reports Encouraging Results for GLPG5101 in NHL in Phase 1/2

                            Details : GLPG5101 is an autologous anti-CD19 CAR-T cell therapy candidate, which is currently being evaluated for the treatment of relapsed/refractory non-hodgkin lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 07, 2024

                            Lead Product(s) : GLPG5101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLPG5101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

                            Details : GLPG5101 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 20, 2024

                            Lead Product(s) : GLPG5101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLPG5301

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-of-Care Manufactured BCMA CAR...

                            Details : GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate which is under phase 1/2 clinical development for the treatment of relapsed/refractory multiple myeloma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 19, 2023

                            Lead Product(s) : GLPG5301

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celyad

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celyad Oncology Announces the Publication of Data from Its Phase 1 THINK Study Of CYAD-01

                            Details : CYAD-01 is an autologous CAR T-cell candidate based on the fusion of the NKG2D receptor with CD3ζ. Co-stimulation is ensured by endogenous DAP10. It is being investigated for hematological malignancies, AML, MDS), or multiple myeloma (MM)] and solid tum...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 09, 2023

                            Lead Product(s) : CYAD-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Galapagos

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLPG5201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galapagos Presented Encouraging Initial Safety and Efficacy Data at 2023 EBMT-EHA For Point-Of-Care Manufactur...

                            Details : GLPG5201 is an anti-CD19/4-1BB CAR-T product candidate, administered as intravenous infusion. It is being developed for relapsed/refractory chronic lymphocytic leukemia (rrCLL) and small lymphocytic lymphoma (rrSLL).

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 09, 2023

                            Lead Product(s) : GLPG5201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Precirix

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : INKEF Capital

                            Deal Size : $87.8 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Precirix Raises EUR 80m in Series B to Advance Its Pipeline of Precision Radiopharmaceuticals

                            Details : The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the ...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            March 16, 2022

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : INKEF Capital

                            Deal Size : $87.8 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Precirix

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Precirix Dosed First Patients in Phase I/II Clinical Study Evaluating CAM-H2 in HER2-Positive Metastatic Cance...

                            Details : CAM-H2 comprises a single-domain antibody targeting HER2, covalently linked to iodine-131. Single-domain antibodies are ideally suited for targeted delivery of radiation to tumors given their size for the treatment of HER2-positive metastatic cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 06, 2021

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Etherna

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Etherna

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : European Commission

                            Deal Size : $8.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Consortium Led by etheRna Immunotherapies Awarded Eu Commission Tiger Grant of Eur 6.9 Million

                            Details : The grant will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic HPV16+ cancers such as head and neck cancer, cervical cancer, anogenital cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 22, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : European Commission

                            Deal Size : $8.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Precirix

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand...

                            Details : Cam-H2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 13, 2020

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth